Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

COGSTATE LTD Board/Management Information 2023

Apr 26, 2023

64644_rns_2023-04-26_3b582f1f-a338-4a9a-be08-538daa1e747a.pdf

Board/Management Information

Open in viewer

Opens in your device viewer

ASX Announcement

27 April 2023

==> picture [213 x 195] intentionally omitted <==

Appointment of Joint Company Secretary

Cogstate (ASX.CGS) is pleased to announce that Ms Kristi Geddes has been appointed as Company Secretary with effect from 27 April 2023. Ms Geddes will be a Joint Company Secretary with Mr David Franks, who was appointed as Company Secretary of Cogstate in February 2021.

Ms Geddes is currently General Counsel at Cogstate. She has 20 years’ legal experience in private practice and inhouse roles, and has undergraduate and post graduate qualifications across law, health and psychological science.

This announcement has been approved for release by the Board of Cogstate Ltd.

About Cogstate

Cogstate Ltd (ASX:CGS) is the neuroscience technology company optimising brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Cogstate technologies provide rapid, reliable and highly sensitive computerised cognitive tests across a growing list of domains and support electronic clinical outcome assessment (eCOA) solutions to replace costly and error-prone paper assessments with real-time data capture. The company’s clinical trials solutions include quality assurance services for study endpoints that combine innovative operational approaches, advanced analytics and scientific consulting. For 20 years, Cogstate has proudly supported the leading-edge research needs of biopharmaceutical companies and academic institutions and the clinical care needs of physicians and patients around the world. In the Healthcare market, in August 2019 Cogstate entered into an exclusive licensing agreement with the pharmaceutical company Eisai, under which Eisai will market Cogstate technologies as digital cognitive assessment tools in Japanese markets. In October 2020, Cogstate extended its agreement with Eisai to the Rest of the World. The product, branded as NouKNOW, launched in Japan on 31 March 2020 (nouknow.jp). For more information, please visit www.cogstate.com.

For further information contact:

Brad O’Connor, Chief Executive Officer, [email protected]